Eli Lilly breaks off sepsis deal
This article was originally published in Clinica
Eli Lilly has told point-of-care diagnostics company PharmaNetics that it is terminating their two-year old agreement to develop a sepsis monitoring test. Lilly has cited the test's failure to provide results across a wide therapeutic range "with the precision originally specified in the marketing characteristics established at the inception of the project". PharmaNetics claims that there is no known method capable of meeting all the originally targeted specifications.